EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia

Ikuto Tsukiyama iD, Takashi Iwata, Tomoko Takeuchi, Ryoko Inuzuka Kato, Masaki Sakuma, Sumiyo Tsukiyama, Mana Kato, Yoshiaki Ikeda, Wataru Ohashi, Akihito Kubo, Naoharu Mori

Supportive Care in Cancer · 2023

DOI: 10.1007/s00520-023-08097-4 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Supportive Care in Cancer, 2023. Verfasst von Ikuto Tsukiyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Onco-pharmacology, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Aichi, 468-8503, Japan. iktkym8@meijo-u.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cancer-associated cachexia, a multifactorial syndrome involving loss of muscle mass and anorexia, is an unremitting problem for cancer patients. Anamorelin has become available for cancer-associated cachexia, but early discontinuation is common in clinical practice. This study aimed to explore factors related to the early discontinuation of anamorelin and its relationship to survival. Patients and methods This prospective, observational study of multimodal clinical practice involved patients who took anamorelin (100 mg) for cancer-associated cachexia at Aichi Medical University Hospital between 14 May 2021 and 31 March 2022. In July 2022, clinical data were extracted from electronic clinical records. Patients who discontinued anamorelin less than 4 weeks after initiation were defined as the early discontinuation group, and their clinical data and survival time were compared with those of the continuation group. This study was approved by the Ethics Committee of the university (approval no. 2021-124).

Results

Of the 42 patients treated with anamorelin, 40 (median age 72.5 years, median BMI 18.7 kg/m 2 ) were analyzed, including 13 with non-small cell lung cancer, and 12 with pancreatic, 8 with colorectal, and 7 with gastric cancers. On univariate analysis, the early discontinuation group included more patients with worse performance status (PS) ( p =0.028), low prognostic nutritional index (PNI) ( p =0.001), and no concomitant anticancer drugs ( p =0.003). On multivariate analysis, PS and PNI were related to anamorelin continuation. Survival time was significantly shorter in the early discontinuation group ( p =0.039).

Conclusion

Worse PS and low PNI were associated with early discontinuation of anamorelin. Longer survival time was observed in the continuation group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAgedCachexiaProspective StudiesHydrazinesOligopeptides

Stichwörter der Autor:innen

AnamorelinCancer-associated cachexiaEarly discontinuationPerformance statusPrognostic nutrition indexRisk factor

Substanzen

anamorelinHydrazinesOligopeptides

Autor:innen und Institutionen

  • Clinical Onco-pharmacology, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Aichi, 468-8503, Japan. iktkym8@meijo-u.ac.jp.
  • Department of Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, Nagakute, Japan. iktkym8@meijo-u.ac.jp.
  • Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan. iktkym8@meijo-u.ac.jp.
  • Clinical OMICs and Translational Research Center, Meijo University, Nagoya, Aichi, Japan. iktkym8@meijo-u.ac.jp.
  • Oncology Center, Aichi Medical University School of Medicine and Hospital, Nagakute, Aichi, Japan.
  • Department of Nutrition, Aichi Medical University Hospital, Nagakute, Aichi, Japan.

ORCID-Profile: Ikuto Tsukiyama

Zitieren

APA

Tsukiyama, I., Iwata, T., Takeuchi, T., Kato, R. I., Sakuma, M., Tsukiyama, S., Kato, M., Ikeda, Y., Ohashi, W., Kubo, A., & Mori, N. (2023). Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia. Supportive Care in Cancer. https://doi.org/10.1007/s00520-023-08097-4

Vancouver

Tsukiyama I, Iwata T, Takeuchi T, Kato RI, Sakuma M, Tsukiyama S, et al. Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia. Supportive Care in Cancer. 2023. doi:10.1007/s00520-023-08097-4

BibTeX
@article{Tsukiyama2023,
  author = {Tsukiyama, Ikuto and Iwata, Takashi and Takeuchi, Tomoko and Kato, Ryoko Inuzuka and Sakuma, Masaki and Tsukiyama, Sumiyo and Kato, Mana and Ikeda, Yoshiaki and Ohashi, Wataru and Kubo, Akihito and Mori, Naoharu},
  title = {Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia},
  journal = {Supportive Care in Cancer},
  year = {2023},
  doi = {10.1007/s00520-023-08097-4}
}
Kostenlos starten →